HSP90AA1 and systemic lupus erythematosus: An increased Hsp90 release from PBMCs has previously been reported in patients with active systemic lupus erythematosus and a significantly higher amount of soluble Hsp90 was observed in sera of patients with the chronic inflammatory disorder atherosclerosis compared with healthy subjects’ sera [34], [35].